A.T. Aubakirova

A.T. Aubakirova

Auto-generated profile, based on publicly available information

A.T. Aubakirova

«National Scientific Center of Surgery named after A.N. Syzganov» JSC 2. "Kazakh Institute of Oncology and Radiology" JSC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2026 in ACS Sensors
Verified
Journal Article
Open access
KSKuanysh Seitkamal
Kuanysh Seitkamal
ABAliya Bekmurzayeva
Aliya Bekmurzayeva
KKKanagat Kantoreyeva
Kanagat Kantoreyeva
AAAygul Aubakirova
Aygul Aubakirova
IPIrina Perova
Irina Perova
Daniele TosiDaniele Tosi
Daniele Tosi
Tumor cells release biomarkers, such as CD44, into circulation, offering a minimally invasive window into tumor biology. However, conventional analytical methods often lack the sensitivity and dynamic range needed to detect these markers reliably in complex biological samples. Here, we exploit graphene oxide-coated semi-distributed interferometry to fabricate an optical fiber biosensor for sensitive CD44 detection. To establish the proof-of-concept, we focus on CD44 because of its well-established role as a circulating biomarker in breast cancer. We functionalize the sensor surface with anti-CD44 antibodies, confirm successful biofunctionalization and antibody specificity through complementary surface characterization and immunological assays, and optimize the platform to achieve a wide dynamic range and a limit of detection of 175 aM. Validation using clinical serum samples from breast cancer patients demonstrated a higher signal for cancer patients than for the healthy group, while successful detection of soluble CD44 in urine further demonstrated the biosensor's compatibility with multiple biological matrices. These findings establish the graphene oxide-coated semi-distributed interferometric biosensor as a highly sensitive platform for CD44 detection in clinically relevant samples. The demonstrated performance, together with the adaptability of the underlying SDI sensing architecture, highlights its potential for future development toward the detection of other circulating biomarkers.

16 January 2023 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
AAA.т. Aubakirova
A.т. Aubakirova
GАG. Аbdilova
G. Аbdilova
ANA. Nurgalyeva
A. Nurgalyeva
GAG. Abdigakyeva
G. Abdigakyeva
YSYe. Serikuly
Ye. Serikuly
ABA. Baichalova
A. Baichalova
Relevance: Hepatocellular carcinoma (HCC) ranks sixth among the most common malignant neoplasms in the world and accounts for about 5.6% of all human malignant neoplasms. Despite encouraging progress in the diagnosis and treatment of HCC, the prognosis remains unsatisfactory, i.e., with a 5-year overall survival rate below 10.3%. However, the survival rate can reach 50-74% if early detection and therapeutic intervention are carried out on time. However, unfortunately, about 50% of HCC cases are diagnosed at a late stage. The protein induced by the absence of vitamin K or antagonist-II (PIVKA-II), also known as Dez-γ-carboxyprothrombin (DCP), is another marker specific to HCC. In several studies, elevated PIVKA-II serum levels were associated with HCC. Many authors have proven the PIVKA-II applicability for HCC monitoring. This study aimed to compare the efficiency of alpha-fetoprotein and des-gamma-carboxyprothrombin serological markers in HCC. Methods: The study included the review of published articles on the causes of HCC and the analysis of literature to compare cancer markers efficacy, including PIVKA-II and alpha-fetoprotein (AFP), in detecting HCC. Results: The published results evidence an important role of PIVKA-II in HCC early detection, since PIVKA-II elevation in risk-group patients predicts HCC development in two years. Higher PIVKA-II levels can indicate a bigger tumor or a higher clinical stage. Besides, HCC patients with metastasis to the lymph nodes and distant metastasis had much higher PIVKA-II levels compared to non-metastatic patients. So, high PIVKA-II levels can to a certain extent reflect poor prognosis in HCC patients. Conclusion: The reviewed publications report much higher PIVKA-II serum levels in patients with HCC compared to patients with benign liver diseases or healthy people. Besides, PIVKA-II has a higher diagnostic capacity than AFP due to its higher levels, sensitivity, and specificity. Thus, we can expect high sensitivity and efficiency of the PIVKA-II oncomarker in HCC early diagnostics.

30 June 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ASAlmaty Syzganov National Scientific Center Of Surgery
Almaty Syzganov National Scientific Center Of Surgery
AAAubakirova A
Aubakirova A
AGAbdilova G
Abdilova G
SOSaniya Ossikbayeva
Saniya Ossikbayeva
SASuranchiev A
Suranchiev A
BNButabayev N
Butabayev N
Background. The urinary albumin-to-creatinine ratio is a well-established marker of early kidney damage, endothelial dysfunction, and systemic inflammation. Elevated urinary albumin-to-creatinine ratio levels are linked to increased cardiovascular risk and mortality. During surgical stress, urinary albumin-to-creatinine ratio may reflect vascular and inflammatory changes, yet its prognostic value in surgical patients remains insufficiently studied. Objective: To assess the prognostic significance of urinary albumin-to-creatinine ratio in patients undergoing surgical interventions. Materials and Methods. A retrospective analysis included 171 patients (98 men, 73 women) aged 40–70 years who underwent various surgeries at the National Scientific Center of Surgery named after A.N. Syzganov from March 2022 to March 2025. Random morning urine samples were analyzed for albumin and creatinine, and urinary albumin-to-creatinine ratio was calculated. Measurements were performed using Cobas 303 and 311 analyzers (Roche Diagnostics). Results. The mean age was 53.2 years. Mean urinary creatinine and albumin were 186.67 mmol/L and 243.73 mg/L, with median values of 9.62 mmol/L and 14.7 mg/L, respectively. Median urinary albumin-to-creatinine ratio was 1.72 mg/mmol; mean was 39.72 mg/mmol, indicating skewness. No significant correlation was found between albumin and creatinine (ρ = –0.037; p = 0.631). A moderate, non-significant inverse correlation was observed in the high-level subgroup (n = 6). Conclusion. Although overall correlations were not significant, findings suggest that urinary albumin-to-creatinine ratio may have prognostic potential. Further prospective studies are needed, especially in abdominal surgery settings.

31 March 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ASAlmaty Syzganov National Scientific Center Of Surgery
Almaty Syzganov National Scientific Center Of Surgery
AAA Aubakirova
A Aubakirova
IMI Madadov
I Madadov
BRB Rgebayev
B Rgebayev
MDM Doskhanov
M Doskhanov
VKV Kumar
V Kumar
Annotation Background. Kidney transplantation is the most effective treatment for end-stage chronic kidney disease, improving quality of life and reducing mortality compared with dialysis. The success of transplantation depends on HLA compatibility, immune sensitization, immune status and immunosuppressive therapy. Tacrolimus, a key immunosuppressant, prevents graft rejection by suppressing T-cell activity and is metabolized by CYP3A4 and CYP3A5 enzymes. CYP3A5 gene polymorphisms influence enzyme activity and tacrolimus metabolism. Methods. The review analyzed 46 of 141 publications from PubMed, MEDLINE, Embase, Scopus, and Cochrane Library databases that met the inclusion criteria and focused on the role of CYP3A5 gene polymorphisms in tacrolimus metabolism in renal transplant patients. Results. CYP3A5 gene polymorphisms significantly affect tacrolimus pharmacokinetics. Carriers of the *1 allele (expressers) demonstrated accelerated metabolism requiring higher doses, while patients with the *3/*3 genotype (non-expressers) exhibited slower metabolism, allowing for reduced doses but increasing the risk of toxicity, including nephrotoxicity. An analysis of 46 publications and randomized studies confirmed that CYP3A5 genotyping enables personalized tacrolimus dosing. For expressers, genotyping facilitated faster achievement of therapeutic concentrations, while for non-expressers, it reduced the risk of toxic effects. However, long-term differences in clinical outcomes between groups with and without genotyping remain statistically insignificant, emphasizing the need for larger-scale studies to validate the efficacy of this approach. Conclusion. CYP3A5 polymorphisms play a key role in the personalization of immunosuppressive therapy. Genotyping optimizes tacrolimus dosing and reduces the risk of rejection and toxicity. Integration of pharmacogenetic testing into clinical practice may improve transplantation outcomes.

22 December 2023 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
TJThe Republic Of Kazakhstan «Syzganov National Scientific Center Of Surgery» Jsc
The Republic Of Kazakhstan «Syzganov National Scientific Center Of Surgery» Jsc
AAA.T. Aubakirova
A.T. Aubakirova
LRL.E. Rizabecova
L.E. Rizabecova
GAG.B. Abdilova
G.B. Abdilova
Relevance: According to official WHO data, currently, about 325 million people in the world live with chronic hepatitis B and C, which makes hepatitis one of the most common infectious diseases in the world. There are many scientific studies aimed at a deeper understanding of hepatitis and the development of new methods of treatment and diagnosis. With the help of polymerase chain reaction, more sensitive tests for diagnosing hepatitis have been developed, allowing faster infection detection and treatment initiation. The PCR method for diagnosing hepatitis is justified and relevant, as it is one of the most effective and modern methods for detecting viral infection, which allows you to start treatment earlier and prevent the development of complications. The study aimed to evaluate the PCR method’s efficiency in diagnosing hepatitis. Methods: In this review, the causes of hepatitis were investigated, and a comparative assessment of the effectiveness of various laboratory methods for diagnosing hepatitis, including enzyme immunoassay and polymerase chain reaction, was conducted. The analysis of scientific publications revealed the factors associated with the development of hepatitis and compared the effectiveness of ELISA, used for serological analysis of antibodies to hepatitis viruses, with PCR, designed to detect DNA or RNA of hepatitis viruses. The obtained results provide important information for improving the methods of diagnosis of hepatitis and more effective control of this serious infectious pathology. Results: The analyzed scientific literature has shown that PCR diagnostics has several advantages over other methods of hepatitis diagnosis, such as ELISA, including higher sensitivity and specificity, the ability to detect hidden infections, and faster results. In addition, PCR diagnostics can be used to determine a specific strain of the virus, making it possible to take measures to treat and control infection. All these advantages confirm the scientific validity of using the PCR method in detecting hepatitis. Conclusion: According to global statistics, PCR has a higher sensitivity and specificity in diagnosing hepatitis than ELISA. PCR can also be used to monitor the effectiveness of hepatitis treatment and determine viral load to make decisions about the need for treatment and evaluate its effectiveness.

30 December 2022 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
AAA. Aubakirova
A. Aubakirova
GАG. Аbdilova
G. Аbdilova
ANA. Nurgalyeva
A. Nurgalyeva
GAG. Abdigakyeva
G. Abdigakyeva
YSYe. Serikuly
Ye. Serikuly
ABA. Baichalova
A. Baichalova
Relevance: Hepatocellular carcinoma (HCC) ranks sixth among the most common malignant neoplasms in the world and accounts for about 5.6% of all human malignant neoplasms. Despite encouraging progress in the diagnosis and treatment of HCC, the prognosis remains unsatisfactory, i.e., with a 5-year overall survival rate below 10.3%. However, the survival rate can reach 50-74% if early detection and therapeutic intervention are carried out on time. However, unfortunately, about 50% of HCC cases are diagnosed at a late stage. The protein induced by the absence of vitamin K or antagonist-II (PIVKA-II), also known as Dez-γ-carboxyprothrombin (DCP), is another marker specific to HCC. In several studies, elevated PIVKA-II serum levels were associated with HCC. Many authors have proven the PIVKA-II applicability for HCC monitoring. This study aimed to compare the efficiency of alpha-fetoprotein and des-gamma-carboxyprothrombin serological markers in HCC. Methods: The study included reviewing published articles on the causes of HCC and analyzing literature to compare cancer markers’ efficacy, including PIVKA-II and alpha-fetoprotein (AFP), in detecting HCC. Results: The published results evidence an important role of PIVKA-II in HCC early detection since PIVKA-II elevation in risk-group patients predicts HCC development in two years. Higher PIVKA-II levels can indicate a bigger tumor or a higher clinical stage. Besides, HCC patients with metastasis to the lymph nodes and distant metastasis had much higher PIVKA-II levels than non-metastatic patients. So, high PIVKA-II levels can, to a certain extent, reflect poor prognosis in HCC patients. Conclusion: The reviewed publications report much higher PIVKA-II serum levels in patients with HCC than in patients with benign liver diseases or healthy people. Besides, PIVKA-II has a higher diagnostic capacity than AFP due to its higher levels, sensitivity, and specificity. Thus, we can expect high sensitivity and efficiency of the PIVKA-II tumor marker in early HCC diagnostics.